Press Releases

14 Feb 2019

A Retrospective Study of Medicare claim data shows patients treated...

BTG plc (LSE: BTG), the global healthcare company, today announced the publication of data showing that cancer patients with presumed methotrexate toxicity treated with Voraxaze® (glucarpidase) had shorter hospital stays, lower in-patient mortality, and lower 90-day mortality than those treated with conventional treatment. The study, based on a retrospective review of Medicare claim data, was published in the journal ClinicoEconomics and Outcomes Research.

5 Feb 2019

NHS England expands loco-regional treatment options for colorectal...

BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy.

21 Jan 2019

Australian Patient Treated With DC Bead LUMI™, the first...

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market leading DC Bead®.

8 Jan 2019

BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

Distributed ledger technology is a game changer for managing stock levels of critical antidote.

21 Dec 2018

BTG announces National Reimbursement for TheraSphere® in...

An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®

3 Dec 2018

Arizona Patients Successfully Receive the World’s First...

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters.

20 Nov 2018

Recommended Cash Offer for BTG plc by Boston Scientific Corporation

Recommended Cash Offer for BTG plc by Boston Scientific Corporation

13 Nov 2018

BTG plc: Interim Results 2018

BTG plc (LSE: BTG), the global healthcare company, today announces its Interim Results for the six months ended 30 September 2018.

6 Nov 2018

EKOS™ Control Unit 4.0 simplifies treatment of blood clots

BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS™ CU 4.0 units have been shipped from BTG’s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS™ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS™ devices simultaneously.

4 Oct 2018

BTG plc: close period update

Good first half performance, updating full year sales growth guidance BTG plc (LSE: BTG), the global healthcare company, provides the following update for the six months ended 30 September 2018.